Lower GI 2017

Conclusion

• Cape/5-FU based CRT remains standard

• Oxaliplatin + CRT: more tox, less compliance

• But: DFS improved even if only added to CRT (!?!)

• CAPOX/FOLFOX as induction-/consolidation Tx (?)

• EGFR-/VEGF-Inhibition: no phase III data

• Other pathways: early phase I/II